Adverse reaction Studies Total patients, n Patients with adverse reaction, n (%) (%, min-max) † Nausea (overall incidence) [ 2, 18, 27, 33, 45, 46, 48, 53, 55, 57, 59, 60, 67, 84, 90, 93, 109, 118] 2214 257 (12) (2–41) [ 55] - [ 48]   Intravenous administration [ 18, 27, 33, 46, 48, 53, 59, 90, 118] 1154 199 (17) (2–41) [ 59] - [ 48]   Transdermal application [ 2, 45, 55, 57, 67, 93, 109] 1039 51 (5) (2–32) [ 55] - [ 2]   >1 administration route [ 60, 84] 21 7 (33) (29–36) [ 84] - [ 60] Vomiting (overall incidence) [ 2, 18, 27, 33, 46, 48, 55, 57, 59, 118] 1611 115 (7) (0–64) [ 55] - [ 48]   Intravenous administration [ 18, 27, 33, 46, 48, 59, 118] 972 108 (11) (2–64) [ 59] - [ 48]   Transdermal application [ 2, 55, 57] 639 7 (1) (0–6) [ 55] - [ 2] Nausea and vomiting ‡ [ 7, 38, 41, 54, 66, 69, 73, 85, 87, 115] 4529 591 (13) (0–46) [ 66] - [ 73] Abdominal cramps/stomach ache (overall incidence) [ 18, 26, 27, 39, 41, 54, 55, 59, 73, 85, 87, 93, 115] 1629 88 (5) (1–52) [ 117] - [ 116]   Intravenous administration [ 18, 26, 27, 39, 41, 54, 59, 73, 85, 87, 115] 1253 72 (6) (1–52) [ 18] - [ 26]   Transdermal application [ 55, 93] 376 16 (4) (2–16) [ 55] - [ 93] Halitosis/garlic-like breath (overall incidence) [ 4, 9, 16, 19, 29, 30, 35, 42, 43, 45, 50, 52, 55, 57, 58, 66– 68, 79, 83, 85, 88, 94, 95, 97, 98, 109, 112, 113] 5782 607 (11) (0–100) [ 30] - [ 19, 43, 45, 83, 98]   Intravenous administration [ 16, 85, 94, 98] 239 14 (6) (1–100) [ 85] - [ 98]   Transdermal application [ 4, 19, 29, 30, 42, 45, 50, 52, 55, 57, 58, 66, 67, 79, 83, 88, 95, 109, 112, 113] 5333 556 (10) (0–100) [ 30] - [ 19, 45, 83]   Intravesical administration [ 35, 43, 97] 165 33 (20) (1–100) [ 35] - [ 43]   Oral administration [ 9] 15 4 (27) Diarrhea (overall incidence) [ 2, 18, 41, 54, 57, 85, 93] 1107 27 (2) (1–6) [ 85] - [ 93]   Intravenous administration [ 18, 41, 54, 85] 744 15 (2) (1–6) [ 85] - [ 41]   Transdermal application [ 2, 57, 93] 363 12 (3) (2–6) [ 57] - [ 93]